跳至主要内容
临床试验/NCT04694677
NCT04694677Unknown不适用

Safety of Tranexamic Acid Versus Misoprostol in Reducing Blood Loss in Myomectomy.

Aljazeera Hospital1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2021年1月10日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
60
试验地点
1
主要终点
the number of women who will have less blood loss

研究概览

简要总结

Uterine leiomyomas (fibroids) are the most common benign tumors among women . Fibroids are found in approximately 15% to 30% of women in the reproductive age group

详细描述

Although most of them are asymptomatic, 20-50% of fibroids may cause problems such as heavy menstrual bleeding, anemia, pelvic pain, pressure symptoms from extrinsic compression of the colorectal and urinary tract, infertility, and recurrent pregnancy losses, where surgical intervention is often indicated

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
20 Years 至 50 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • women with myomas

排除标准

  • with with malignant lesions

研究组 & 干预措施

women receiving tranexamic acid

Active Comparator

干预措施: women receiving tranexamic acid (Drug)

women receiving misoprostol

Active Comparator

干预措施: women receiving misoprostol (Drug)

结局指标

主要结局

the number of women who will have less blood loss

时间窗: 48 hours

how many women will have less blood loss

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验